VRTX Stock Recent News

In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks they buy increase in value.

Looking for a good area in which to invest? Consider the healthcare sector.

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). But which of these two companies is the best option for those looking for undervalued stocks?

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Stuart Arbuckle, Executive Vice President and Chief Operating Officer, and David Altshuler, M.D., Ph.D., Executive Vice President, Global Research, and Chief Scientific Officer will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 3:10 p.m. ET. Charles Wagner, Executive Vice Pres.

Deshawn "DJ" Chow is one of just over 100 sickle cell patients who have undergone treatment with new gene therapies. CVS Health CEO David Joyner said private insurers and employer-sponsored health plans are looking at how to create a new risk pool arrangement to help manage the costs of the therapies.

If you're content with market-level returns, investing in an exchange-traded fund (ETF) is the way to go. But if not, you'll need to find stocks that hold the potential to pack more punch.

Vertex Pharmaceuticals (VRTX -0.77%) and AstraZeneca (AZN -1.17%), two of the world's leading drugmakers, missed last year's strong market rally. Both finished 2024 slightly in the red.

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

Healthcare isn't the hottest sector these days. While the S&P 500 has soared nearly 21% over the last 12 months, healthcare stocks as a group are barely in positive territory.